

Mark E Cooper

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5245322/mark-e-cooper-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

395
papers

45,691
citations

97
h-index

207
g-index

412
ext. papers

51,128
ext. citations

8
avg, IF

7.34
L-index

#	Paper	IF	Citations
395	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>New England Journal of Medicine</i> , 2001 , 345, 861-9	59.2	5467
394	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 358, 2560-72	59.2	5250
393	A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. <i>New England Journal of Medicine</i> , 2009 , 361, 2019-32	59.2	1695
392	Mechanisms of diabetic complications. <i>Physiological Reviews</i> , 2013 , 93, 137-88	47.9	1339
391	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <i>Lancet, The</i> , 2014 , 383, 1068-83	40	915
390	Oxidative stress as a major culprit in kidney disease in diabetes. <i>Diabetes</i> , 2008 , 57, 1446-54	0.9	843
389	Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. <i>Journal of Experimental Medicine</i> , 2008 , 205, 2409-17	16.6	784
388	Clinical review: The role of advanced glycation end products in progression and complications of diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1143-52	5.6	715
387	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. <i>Kidney International</i> , 2004 , 65, 2309-20	9.9	685
386	Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1813-21	12.7	640
385	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. <i>Circulation</i> , 2004 , 110, 921-7	16.7	573
384	Reduced bone mass in daughters of women with osteoporosis. <i>New England Journal of Medicine</i> , 1989 , 320, 554-8	59.2	527
383	The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. <i>Kidney International</i> , 1999 , 56, 1627-37	9.9	483
382	Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. <i>Diabetes</i> , 2009 , 58, 1229-36	9.9	399
381	Pathogenesis, prevention, and treatment of diabetic nephropathy. <i>Lancet, The</i> , 1998 , 352, 213-9	40	393
380	Suppression of microRNA-29 expression by TGF- β 1 promotes collagen expression and renal fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 252-65	12.7	385
379	A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. <i>Circulation Research</i> , 2003 , 92, 785-92	15.7	363

378	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. <i>Nature Medicine</i> , 2012 , 18, 926-33	50.5	339
377	Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. <i>Diabetes</i> , 2008 , 57, 2461-9	0.9	334
376	Myocardial infarction increases ACE2 expression in rat and humans. <i>European Heart Journal</i> , 2005 , 26, 369-75; discussion 322-4	9.5	324
375	RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 742-52	12.7	323
374	Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. <i>Hypertension</i> , 2003 , 41, 392-7	8.5	307
373	Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). <i>Journal of Clinical Investigation</i> , 2001 , 108, 1853-63	15.9	303
372	Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. <i>Diabetes</i> , 2008 , 57, 460-9	0.9	281
371	miR-200a Prevents renal fibrogenesis through repression of TGF- β expression. <i>Diabetes</i> , 2011 , 60, 280-7	0.9	279
370	Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2016 , 12, 73-81	14.9	277
369	NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. <i>Circulation</i> , 2013 , 127, 1888-902	16.7	273
368	AGE, RAGE, and ROS in diabetic nephropathy. <i>Seminars in Nephrology</i> , 2007 , 27, 130-43	4.8	262
367	Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. <i>Circulation</i> , 1998 , 98, 2621-8	16.7	259
366	Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. <i>Diabetes</i> , 2004 , 53, 1813-23	0.9	258
365	Role of advanced glycation end products in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, S254-8	12.7	248
364	Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1237-54	12.7	246
363	Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. <i>Nature Reviews Drug Discovery</i> , 2009 , 8, 417-29	64.1	245
362	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15018	51.1	241
361	Diabetes and Kidney Disease: Role of Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2016 , 25, 657-684	4	240

360	Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. <i>Circulation</i> , 2002 , 106, 246-53	16.7	236
359	Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. <i>Diabetes</i> , 2004 , 53, 989-97	0.9	233
358	ACE2, a new regulator of the renin-angiotensin system. <i>Trends in Endocrinology and Metabolism</i> , 2004 , 15, 166-9	8.8	230
357	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1540-6	12.7	225
356	Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. <i>Journal of Hypertension</i> , 2005 , 23, 463-73	1.9	225
355	Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. <i>Diabetes Care</i> , 2013 , 36, 3460-8	14.6	219
354	Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2484-94	12.7	218
353	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. <i>Kidney International</i> , 2011 , 80, 282-7	9.9	217
352	The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. <i>FASEB Journal</i> , 2003 , 17, 1762-4	0.9	217
351	E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. <i>Diabetes</i> , 2010 , 59, 1794-802	0.9	212
350	Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. <i>Circulation</i> , 2007 , 115, 2178-87	16.7	212
349	Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. <i>FASEB Journal</i> , 2004 , 18, 176-8	0.9	210
348	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. <i>Kidney International</i> , 2013 , 83, 517-23	9.9	209
347	Lowering blood pressure reduces renal events in type 2 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 883-92	12.7	205
346	Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. <i>Diabetes</i> , 2002 , 51, 3274-82	0.9	203
345	Retinal neovascularization is prevented by blockade of the renin-angiotensin system. <i>Hypertension</i> , 2000 , 36, 1099-104	8.5	201
344	Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. <i>American Journal of Pathology</i> , 2004 , 164, 1389-97	5.8	184
343	Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 2363-72	12.7	180

342	Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. <i>Circulation</i> , 2004 , 109, 1536-42	16.7	180
341	Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. <i>Circulation Research</i> , 2010 , 107, 888-97	15.7	179
340	AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. <i>Kidney International</i> , 2004 , 66, 2137-47	9.9	174
339	Diabetic nephropathy: diagnosis and treatment. <i>Nature Reviews Endocrinology</i> , 2013 , 9, 713-23	15.2	164
338	miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. <i>Clinical Science</i> , 2015 , 129, 1237-49	6.5	161
337	Epigenetics: mechanisms and implications for diabetic complications. <i>Circulation Research</i> , 2010 , 107, 1403-13	15.7	157
336	Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. <i>Gastroenterology</i> , 2002 , 123, 1667-76	13.3	156
335	Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. <i>Circulation</i> , 2009 , 120, 2095-104	16.7	149
334	Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. <i>Kidney International</i> , 1997 , 51, 1553-67	9.9	149
333	Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. <i>European Heart Journal</i> , 2009 , 30, 1128-35	9.5	147
332	ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. <i>Diabetes</i> , 2008 , 57, 1018-25	0.9	147
331	Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 75-83	7.4	139
330	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. <i>Journal of Hepatology</i> , 2001 , 35, 376-85	13.4	139
329	Transforming growth factor- β -mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. <i>Kidney International</i> , 2014 , 85, 352-61	9.9	137
328	Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. <i>Diabetes</i> , 2004 , 53, 2921-30	0.9	135
327	Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 761-7	6.9	133
326	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , 2016 , 39, 694-700	14.6	130
325	Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 2139-51	12.7	130

324	Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. <i>Hypertension</i> , 2011 , 58, 2-7	8.5	129
323	A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). <i>Kidney International</i> , 1998 , 54, 343-52	9.9	129
322	Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. <i>Endocrinology</i> , 2002 , 143, 4907-15	4.8	127
321	Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. <i>Clinical Science</i> , 2013 , 124, 191-202	6.5	126
320	Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. <i>American Journal of Hypertension</i> , 2004 , 17, 315-385	2.3	126
319	Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. <i>Circulation Research</i> , 2012 , 110, 1067-76	15.7	121
318	Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. <i>American Journal of Pathology</i> , 1999 , 155, 429-40	5.8	121
317	Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 2125-38	12.7	120
316	Interactions between renin angiotensin system and advanced glycation in the kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 2976-84	12.7	118
315	Imatinib attenuates diabetes-associated atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 935-42	9.4	116
314	A low-sodium diet potentiates the effects of losartan in type 2 diabetes. <i>Diabetes Care</i> , 2002 , 25, 663-71	14.6	116
313	Comparison of different measures of urinary protein excretion for prediction of renal events. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1355-60	12.7	114
312	Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiotensin. <i>American Journal of Pathology</i> , 2003 , 163, 879-87	5.8	112
311	Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1903-9	9.4	111
310	Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. <i>Kidney International</i> , 1996 , 50, 627-34	9.9	111
309	Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 295-307	9.4	109
308	Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 363-73	12.7	106
307	Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 1773-87	12.7	106

306	Pathogenesis of diabetic nephropathy. <i>Journal of Diabetes Investigation</i> , 2011 , 2, 243-7	3.9	104
305	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000 , 1, 328-35	3	103
304	Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. <i>Endocrinology</i> , 2007 , 148, 886-95	4.8	99
303	The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. <i>American Journal of Hypertension</i> , 2004 , 17, 16S-20S; quiz A2-4	2.3	99
302	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1610-1619	6.7	98
301	PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. <i>Kidney International</i> , 2001 , 59, 1324-32	9.9	98
300	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. <i>Kidney International</i> , 2000 , 58, 2437-51	9.9	98
299	Dedifferentiation of immortalized human podocytes in response to transforming growth factor- β model for diabetic podocytopathy. <i>Diabetes</i> , 2011 , 60, 1779-88	0.9	97
298	Mechanisms of diabetic nephropathy: role of hypertension. <i>Hypertension</i> , 2006 , 48, 519-26	8.5	97
297	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005 , 149, 408-13	4.9	97
296	The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. <i>American Journal of Pathology</i> , 2003 , 162, 151-60	5.8	97
295	Advanced glycation end products and diabetic complications. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 1205-23	5.9	94
294	The role of AGEs in cardiovascular disease. <i>Current Pharmaceutical Design</i> , 2008 , 14, 979-86	3.3	93
293	Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. <i>Diabetes</i> , 2017 , 66, 2266-2277	0.9	92
292	Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 784-97	12.7	92
291	Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. <i>Free Radical Biology and Medicine</i> , 2012 , 52, 716-723	7.8	91
290	Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. <i>Nature Reviews Nephrology</i> , 2010 , 6, 332-41	14.9	90
289	PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 2399-405	4.3	89

288	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. <i>Diabetes</i> , 2017 , 66, 2691-2703	0.9	88
287	Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F763-70	4.3	88
286	Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2001 , 12, 2098-2107	12.7	88
285	Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. <i>Diabetes</i> , 2014 , 63, 3091-103	0.9	87
284	Oxidative stress, Nox isoforms and complications of diabetes--potential targets for novel therapies. <i>Journal of Cardiovascular Translational Research</i> , 2012 , 5, 509-18	3.3	87
283	Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. <i>Diabetologia</i> , 2016 , 59, 379-89	10.3	86
282	NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. <i>Antioxidants and Redox Signaling</i> , 2014 , 20, 2726-40	8.4	84
281	Targeted reduction of advanced glycation improves renal function in obesity. <i>Kidney International</i> , 2011 , 80, 190-8	9.9	83
280	Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. <i>Diabetes</i> , 2010 , 59, 3208-15	0.9	83
279	Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 295, E323-30	6	83
278	Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. <i>Archives of Biochemistry and Biophysics</i> , 2003 , 419, 55-62	4.1	83
277	Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 579-591	6.4	82
276	Advanced glycation end products and diabetic nephropathy. <i>American Journal of Therapeutics</i> , 2005 , 12, 562-72	1	82
275	Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. <i>Diabetes</i> , 2010 , 59, 3198-207	0.9	81
274	ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) ²⁷ rat. <i>Diabetes</i> , 2002 , 51, 3283-9	0.9	80
273	Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. <i>Hypertension</i> , 2000 , 36, 561-8	8.5	77
272	Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 441-9	7.4	75
271	The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). <i>Medical Journal of Australia</i> , 2006 , 185, 140-4	4	75

270	Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 3061-71	12.7	75
269	Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. <i>Diabetes Care</i> , 2002 , 25, 1072-7	14.6	75
268	Nox-4 deletion reduces oxidative stress and injury by PKC- β -associated mechanisms in diabetic nephropathy. <i>Physiological Reports</i> , 2014 , 2, e12192	2.6	74
267	Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 68-78	12.7	74
266	Anemia with impaired erythropoietin response in diabetic patients. <i>Archives of Internal Medicine</i> , 2005 , 165, 466-9		74
265	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. <i>Kidney International</i> , 2000 , 57, 1882-94	9.9	74
264	Long-term glycemic control and the rate of progression of early diabetic kidney disease. <i>Kidney International</i> , 1993 , 44, 855-9	9.9	74
263	Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 823-30	9.4	71
262	Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. <i>Hypertension</i> , 2004 , 43, 276-81	8.5	71
261	Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. <i>Hypertension</i> , 1999 , 34, 408-14	8.5	71
260	Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. <i>Hypertension</i> , 1998 , 32, 778-85	8.5	70
259	Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics. <i>Journal of Hypertension</i> , 1988 , 6, 1009-16	1.9	70
258	Role of nephrin in renal disease including diabetic nephropathy. <i>Seminars in Nephrology</i> , 2002 , 22, 393-8	4.8	70
257	Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. <i>Diabetologia</i> , 2017 , 60, 927-937	10.3	69
256	Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. <i>Journal of Hypertension</i> , 2002 , 20, 985-92	1.9	69
255	Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. <i>Clinical Science</i> , 2016 , 130, 711-20	6.5	68
254	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. <i>Kidney International</i> , 2002 , 61, 31-9	9.9	68
253	Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. <i>American Journal of Kidney Diseases</i> , 2001 , 37, 890-9	7.4	67

252	Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. <i>Kidney International</i> , 1999 , 71, S31-6	9.9	67
251	Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. <i>Diabetes</i> , 1994 , 43, 1221-8	0.9	67
250	Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. <i>Kidney International</i> , 1998 , 54, 1052-62	9.9	66
249	Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. <i>Circulation Research</i> , 2000 , 86, 158-65	15.7	65
248	Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. <i>Diabetes</i> , 2014 , 63, 3915-25	0.9	64
247	Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. <i>Journal of Hypertension</i> , 2010 , 28, 780-8	1.9	64
246	Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. <i>Endocrinology</i> , 2004 , 145, 860-6	4.8	64
245	Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. <i>Kidney International</i> , 2000 , 58, 1469-80	9.9	64
244	ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 771-9	12.7	63
243	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. <i>Diabetes Care</i> , 2004 , 27, 874-9	14.6	61
242	Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. <i>Kidney International</i> , 2001 , 60, 715-21	9.9	60
241	Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. <i>Kidney International</i> , 2004 , 66, 1167-72	9.9	59
240	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. <i>Kidney International</i> , 2010 , 78, 287-95	9.9	58
239	Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. <i>Journal of Hypertension</i> , 2003 , 21, 209-16	1.9	57
238	Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. <i>Journal of Biological Chemistry</i> , 2007 , 282, 11722-31	5.4	56
237	Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition. <i>Circulation Research</i> , 2000 , 87, 1133-40	15.7	55
236	Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. <i>Kidney International</i> , 1999 , 55, 907-16	9.9	54
235	Cellular mechanisms of diabetic vascular hypertrophy. <i>Microvascular Research</i> , 1999 , 57, 8-18	3.7	54

234	Serum lipids and the progression of nephropathy in type 1 diabetes. <i>Diabetes Care</i> , 2006 , 29, 317-22	14.6	53
233	Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. <i>Diabetes</i> , 1990 , 39, 1575-9	0.9	53
232	Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion. <i>Journal of Hypertension</i> , 2001 , 19, 1075-81	1.9	52
231	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1199-1208	6.7	51
230	Optimizing treatment of hypertension in patients with diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 283, 3177-9	27.4	51
229	Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. <i>Diabetes</i> , 2012 , 61, 2105-13	0.9	50
228	The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. <i>Journal of Biological Chemistry</i> , 2003 , 278, 25783-9	5.4	50
227	Role of angiotensin II in tubulointerstitial injury. <i>Seminars in Nephrology</i> , 2001 , 21, 554-62	4.8	50
226	AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. <i>Hypertension</i> , 2015 , 65, 1073-81	8.5	49
225	Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. <i>Diabetes</i> , 2011 , 60, 3073-80	0.9	49
224	Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. <i>Diabetes Care</i> , 2015 , 38, 1891-7	14.6	48
223	Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 2195-2203	9.4	48
222	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009 , 54, 59-69	7.4	48
221	Diabetic vascular complications. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997 , 24, 770-5	3	48
220	Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. <i>Atherosclerosis</i> , 1998 , 136, 125-31	3.1	48
219	Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. <i>Diabetes Care</i> , 2006 , 29, 2210-7	14.6	47
218	Hypertension and diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , 2002 , 11, 221-8	3.5	47
217	Direct Endothelial Nitric Oxide Synthase Activation Provides Atheroprotection in Diabetes-Accelerated Atherosclerosis. <i>Diabetes</i> , 2015 , 64, 3937-50	0.9	46

216	Use of genetic mouse models in the study of diabetic nephropathy. <i>Current Diabetes Reports</i> , 2004 , 4, 435-40	5.6	46
215	Reduced tubular cation transport in diabetes: prevented by ACE inhibition. <i>Kidney International</i> , 2003 , 63, 2152-61	9.9	46
214	Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 55-62	4.3	45
213	Heat shock protein expression in diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 295, F1817-24	4.3	45
212	Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. <i>Kidney International</i> , 2003 , 63, 1265-75	9.9	44
211	Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. <i>Diabetes</i> , 2014 , 63, 2845-53	0.9	43
210	Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. <i>Journal of Hypertension</i> , 2005 , 23, 153-64	1.9	43
209	Effect of early menopause on bone mass in normal women and patients with osteoporosis. <i>American Journal of Medicine</i> , 1988 , 85, 213-6	2.4	43
208	Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 654-61	5.1	42
207	Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. <i>Hypertension</i> , 2012 , 60, 98-105	8.5	41
206	Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. <i>Clinical Science</i> , 2001 , 100, 591-599	6.5	41
205	Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. <i>Kidney International</i> , 1999 , 56, 211-21	9.9	41
204	Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. <i>Clinical Science</i> , 2012 , 123, 519-29	6.5	40
203	The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 311, 456-66	4.7	40
202	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. <i>Kidney International</i> , 2002 , 61, 1696-706	9.9	40
201	New insights into the significance of microalbuminuria. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 83-91	3.5	40
200	Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. <i>Diabetes</i> , 2018 , 67, 2657-2667	2.6	40
199	Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects. <i>European Journal of Pharmacology</i> , 1995 , 280, 91-4	5.3	39

198	Serum total renin is increased before microalbuminuria in diabetes. <i>Kidney International</i> , 1996 , 50, 902-7	9.9	39
197	Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 406-421	15.9	39
196	Circulating bone morphogenetic protein-7 and transforming growth factor- β are better predictors of renal end points in patients with type 2 diabetes mellitus. <i>Kidney International</i> , 2013 , 83, 278-84	9.9	38
195	Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. <i>Nephrology</i> , 2005 , 10, 167-73	2.2	37
194	Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. <i>Journal of Hypertension</i> , 2002 , 20, 1615-24	1.9	37
193	Cardiovascular Disease and Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018 , 38, 217-232	4.8	36
192	50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. <i>Diabetologia</i> , 2015 , 58, 1708-14	10.3	36
191	Hypertension and diabetes: role of the renin-angiotensin system. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006 , 35, 469-90, vii	5.5	36
190	Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis. <i>Circulation Research</i> , 2020 , 127, 877-892	15.7	35
189	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. <i>Diabetes</i> , 2016 , 65, 1085-98	0.9	34
188	The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 299, F528-35	4.3	34
187	Pathophysiology of diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , 1998 , 47, 3-6	12.7	34
186	Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. <i>Journal of Hypertension</i> , 2006 , 24, S57-63	1.9	34
185	Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat. <i>Journal of Comparative Neurology</i> , 2003 , 456, 29-38	3.4	34
184	Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. <i>Kidney International</i> , 2003 , 64, 565-71	9.9	34
183	High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. <i>Journal of Molecular Endocrinology</i> , 2005 , 35, 39-48	4.5	34
182	Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2) ²⁷ rat. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1343-9	4.3	34
181	New insights into the use of biomarkers of diabetic nephropathy. <i>Advances in Chronic Kidney Disease</i> , 2014 , 21, 318-26	4.7	33

180	Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. <i>Connective Tissue Research</i> , 1999 , 40, 295-303	3.3	33
179	Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. <i>Kidney International</i> , 1992 , 41, 898-903	9.9	33
178	Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D ² trial. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 455-62	3.3	32
177	Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1437-1448	12.7	32
176	ACE2 deficiency shifts energy metabolism towards glucose utilization. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, 406-15	12.7	32
175	Amylin stimulates plasma renin concentration in humans. <i>Hypertension</i> , 1995 , 26, 460-4	8.5	32
174	Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease. <i>Antioxidants and Redox Signaling</i> , 2013 , 19, 331-43	8.4	31
173	Nox-4 and progressive kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 74-80	3.5	31
172	Amylin as a growth factor during fetal and postnatal development of the rat kidney. <i>Kidney International</i> , 1998 , 53, 25-30	9.9	31
171	Renal microvascular injury in diabetes: RAGE and redox signaling. <i>Antioxidants and Redox Signaling</i> , 2007 , 9, 331-42	8.4	31
170	c-Jun NH2-terminal kinase activity in subcutaneous adipose tissue but not nuclear factor-kappaB activity in peripheral blood mononuclear cells is an independent determinant of insulin resistance in healthy individuals. <i>Diabetes</i> , 2009 , 58, 1259-65	0.9	30
169	Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man. <i>American Journal of Nephrology</i> , 2011 , 34, 347-55	4.6	30
168	SPARC gene expression is reduced in early diabetes-related kidney growth. <i>Kidney International</i> , 1995 , 48, 1216-25	9.9	29
167	Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. <i>Kidney International</i> , 1992 , 41, 904-11	9.9	29
166	The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis. <i>Diabetologia</i> , 2016 , 59, 1778-90	10.3	29
165	Renoprotective effects of renin-angiotensin-system inhibitors. <i>Lancet, The</i> , 2006 , 367, 899-900; author reply 900-2	4.0	28
164	Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1043, 644-54	6.5	28
163	Targets to retard the progression of diabetic nephropathy. <i>Kidney International</i> , 2005 , 68, 1439-45	9.9	28

162	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. <i>American Journal of Nephrology</i> , 2014 , 40, 572-81	4.6	27
161	Calcitonin receptor isoforms expressed in the developing rat kidney. <i>Kidney International</i> , 2003 , 63, 416-26	3.6	27
160	Processed foods drive intestinal barrier permeability and microvascular diseases. <i>Science Advances</i> , 2021 , 7,	14.3	27
159	Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. <i>Nephrology</i> , 2013 , 18, 47-56	2.2	26
158	Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. <i>Clinical Science</i> , 2014 , 127, 485-97	6.5	26
157	The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. <i>Kidney International</i> , 2004 , S105-7	9.9	26
156	Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE ^{-/-} mice. <i>Clinical Science</i> , 2016 , 130, 1363-74	6.5	26
155	Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 306, F773-80	4.3	25
154	Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction. <i>Frontiers in Bioscience - Scholar</i> , 2011 , 3, 709-29	2.4	25
153	Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. <i>Journal of Hypertension</i> , 2002 , 20, 707-14	1.9	25
152	Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. <i>Journal of Hypertension</i> , 1996 , 14, 601-7	1.9	25
151	Pathophysiological Links Between Diabetes and Blood Pressure. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 585-594	3.8	24
150	Compression force sensing regulates integrin α 5 β 1 adhesive function on diabetic platelets. <i>Nature Communications</i> , 2018 , 9, 1087	17.4	24
149	Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. <i>Diabetology and Metabolic Syndrome</i> , 2014 , 6, 86	5.6	24
148	Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. <i>Atherosclerosis</i> , 2014 , 235, 444-8	3.1	24
147	Use of genetic mouse models in the study of diabetic nephropathy. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 197-202	6	24
146	Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. <i>Amino Acids</i> , 2014 , 46, 321-6	3.5	23
145	Advanced-glycation end products in insulin-resistant states. <i>Current Hypertension Reports</i> , 2005 , 7, 96-102	2.7	23

144	Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. <i>Journal of Hypertension</i> , 1998 , 16, 1603-9	1.9	23
143	Microalbuminuria in diabetes. <i>Medical Journal of Australia</i> , 1994 , 161, 265-268	4	23
142	Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. <i>Kidney International</i> , 2004 , 66, 1090-8	9.9	22
141	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. <i>Diabetologia</i> , 2019 , 62, 1988-1997	10.3	21
140	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000011	4.5	21
139	Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor- β in diabetic nephropathy. <i>Kidney International</i> , 2011 , 79, 199-209	9.9	21
138	The relationship between heat shock protein 72 expression in skeletal muscle and insulin sensitivity is dependent on adiposity. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 1556-61	12.7	21
137	Apoptosis and angiotensin II: yet another renal regulatory system?. <i>Nephron Experimental Nephrology</i> , 2001 , 9, 295-300		21
136	Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. <i>Journal of Vascular Research</i> , 1995 , 32, 183-9	1.9	21
135	Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. <i>Hypertension</i> , 2020 , 75, 1091-1101	8.5	20
134	Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 1782-92	12.7	20
133	Metabolic memory: implications for diabetic vascular complications. <i>Pediatric Diabetes</i> , 2009 , 10, 343-6	3.6	20
132	Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. <i>Clinical Science</i> , 2020 , 134, 239-259	6.5	20
131	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. <i>Diabetes</i> , 2020 , 69, 83-98	0.9	20
130	Glycation in diabetic nephropathy. <i>Amino Acids</i> , 2012 , 42, 1185-92	3.5	19
129	Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. <i>Journal of Hypertension</i> , 2005 , 23, 2071-82	1.9	19
128	Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes. <i>Kidney International</i> , 2005 , 67, 2494-9	9.9	19
127	Glucose homeostasis can be differentially modulated by varying individual components of a western diet. <i>Journal of Nutritional Biochemistry</i> , 2013 , 24, 1251-7	6.3	18

126	Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. <i>American Journal of Nephrology</i> , 2010 , 32, 73-82	4.6	18
125	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. <i>Journal of Hypertension</i> , 2007 , 25, 871-6	1.9	18
124	Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis. <i>Experimental Cell Research</i> , 2004 , 293, 31-42	4.2	18
123	Lipids and diabetic renal disease. <i>Current Diabetes Reports</i> , 2005 , 5, 445-8	5.6	18
122	Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. <i>Diabetologia</i> , 2019 , 62, 1712-1726	10.3	17
121	Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolemia. <i>Medical Journal of Australia</i> , 1990 , 152, 480-483	4	17
120	Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. <i>Nature Reviews Nephrology</i> , 2021 , 17, 725-739	14.9	17
119	Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 2293-9	4.3	16
118	Antiproteinuric effect of RAS blockade: new mechanisms. <i>Current Hypertension Reports</i> , 2004 , 6, 383-92	4.7	16
117	Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action. <i>Journal of Hypertension</i> , 1998 , 16, 793-9	1.9	16
116	Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1992 , 19, 343-7	3	16
115	Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
114	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. <i>American Journal of Kidney Diseases</i> , 2013 , 61, 238-46	7.4	15
113	Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 414-21	12.7	15
112	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. <i>Clinical and Experimental Nephrology</i> , 2006 , 10, 193-200	2.5	15
111	Vascular changes in the diabetic kidney: effects of ACE inhibition. <i>Journal of Diabetes and Its Complications</i> , 1995 , 9, 296-300	3.2	15
110	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019 , 73, 309-315	7.4	15
109	Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. <i>Metabolism: Clinical and Experimental</i> , 1998 , 47, 24-7	12.7	14

108	Agents in development for the treatment of diabetic nephropathy. <i>Expert Opinion on Emerging Drugs</i> , 2008 , 13, 447-63	3.7	14
107	Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15, 347-54	4.3	14
106	Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 684-692	12.7	14
105	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 862-872	6.9	13
104	Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with Type 1 diabetes. <i>Clinical Science</i> , 2013 , 124, 617-26	6.5	13
103	Tandem inhibition of PKC in Diabetic nephropathy: it takes two to tango?. <i>Diabetes</i> , 2013 , 62, 1010-1	0.9	13
102	Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998 , 25, 653-60	3	13
101	Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1126, 101-6	6.5	13
100	Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. <i>Clinical Science</i> , 2003 , 104, 341-347	6.5	13
99	Diabetes and hypertension. Australian Diabetes Society position statement. <i>Medical Journal of Australia</i> , 1995 , 163, 372-5	4	13
98	Effects of liver transplantation and resection on lipid parameters: a longitudinal study. <i>ANZ Journal of Surgery</i> , 1996 , 66, 743-6	1	13
97	Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy. <i>Current Pharmaceutical Design</i> , 2004 , 10, 3361-72	3.3	13
96	Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1). <i>Diabetes</i> , 2018 , 67, 755-768	0.9	12
95	Plasma advanced glycation end products (AGEs) and NF- κ B activity are independent determinants of diastolic and pulse pressure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, 129-38	5.9	12
94	Diabetes: bardoxolone improves kidney function in type 2 diabetes. <i>Nature Reviews Nephrology</i> , 2011 , 7, 552-3	14.9	12
93	Agents in development for the treatment of diabetic nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 279-94	5.9	12
92	Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. <i>Kidney International</i> , 2003 , 63, 1577-9	9.9	12
91	Drug administration in patients with diabetes mellitus. Safety considerations. <i>Drug Safety</i> , 1998 , 18, 441-55	5.5	12

90	Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. <i>Journal of Diabetes and Its Complications</i> , 1995 , 9, 252-4	3.2	12
89	Increased density of renal amylin binding sites in experimental hypertension. <i>Hypertension</i> , 1997 , 30, 455-60	8.5	12
88	Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. <i>Clinical Science</i> , 2003 , 104, 341	6.5	11
87	Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. <i>Journal of Hypertension</i> , 1996 , 14, S11??14	1.9	11
86	The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. <i>Journal of the American Geriatrics Society</i> , 1990 , 38, 10-4	5.6	11
85	Comparison of early renal dysfunction in type I and type II diabetes: differing associations with blood pressure and glycaemic control. <i>Diabetes Research and Clinical Practice</i> , 1988 , 4, 133-41	7.4	11
84	Complications of Diabetes Mellitus 2016 , 1484-1581		11
83	Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study). <i>Diabetes Research and Clinical Practice</i> , 2016 , 113, 143-51	7.4	11
82	Targeting the CDA1/CDA1BP1 Axis Retards Renal Fibrosis in Experimental Diabetic Nephropathy. <i>Diabetes</i> , 2019 , 68, 395-408	0.9	11
81	New Glucose-Lowering Agents for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2018 , 25, 149-157	4.7	10
80	Set7 mediated interactions regulate transcriptional networks in embryonic stem cells. <i>Nucleic Acids Research</i> , 2016 , 44, 9206-9217	20.1	10
79	Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. <i>Clinical Science</i> , 2001 , 100, 591	6.5	10
78	A promising outlook for diabetic kidney disease. <i>Nature Reviews Nephrology</i> , 2019 , 15, 68-70	14.9	10
77	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor- β and Increasing Resistance to Apoptosis. <i>Diabetes</i> , 2018 , 67, 960-973	0.9	9
76	Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?. <i>Cardiovascular Drug Reviews</i> , 2001 , 19, 75-86		9
75	Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats. <i>Clinical and Experimental Hypertension</i> , 2004 , 26, 69-80	2.2	9
74	Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats. <i>Clinical and Experimental Hypertension</i> , 2002 , 24, 371-81	2.2	9
73	The management of diabetic proteinuria. Which antihypertensive agent?. <i>Drugs and Aging</i> , 1992 , 2, 301-4.7		9

72	Glomerular filtration rate in early experimental diabetes. <i>The Journal of Diabetic Complications</i> , 1988 , 2, 8-11		9
71	Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME [®] trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 2103-2111	4.3	9
70	What are new avenues for renal protection, in addition to RAAS inhibition?. <i>Current Hypertension Reports</i> , 2012 , 14, 100-10	4.7	8
69	Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. <i>Diabetes Care</i> , 2008 , 31, 445-7	14.6	8
68	Microalbuminuria and diabetic cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2003 , 5, 350-7	6	8
67	Combination antihypertensive therapy in the treatment of diabetic nephropathy. <i>Diabetes Technology and Therapeutics</i> , 2002 , 4, 313-21	8.1	8
66	Is there a role for endothelin antagonists in diabetic renal disease?. <i>Diabetes, Obesity and Metabolism</i> , 2000 , 2, 15-24	6.7	8
65	Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney. <i>American Journal of Physiology - Renal Physiology</i> , 1998 , 274, F51-62	4.3	8
64	Intermittent diabetic microalbuminuria: association with blood pressure, glycemic control, and protein intake. <i>The Journal of Diabetic Complications</i> , 1989 , 3, 92-8		8
63	Protective Effect of Inflammasome Activation by Hydrogen Peroxide in a Mouse Model of Septic Shock. <i>Critical Care Medicine</i> , 2017 , 45, e184-e194	1.4	7
62	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type ² Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 522-531	7.4	7
61	Eplerenone does not attenuate diabetes-associated atherosclerosis. <i>Journal of Hypertension</i> , 2009 , 27, 1431-8	1.9	7
60	Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. <i>Diabetes Research and Clinical Practice</i> , 2005 , 70, 201-8	7.4	7
59	The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON-2). <i>Medical Journal of Australia</i> , 2006 , 185, 259-62	4	7
58	Diabetic nephropathy. <i>Diabetes Technology and Therapeutics</i> , 1999 , 1, 489-96	8.1	7
57	Diabetes and hypertension: prognostic and therapeutic considerations. <i>Blood Pressure</i> , 1995 , 4, 329-38	1.7	7
56	Complications of Diabetes Mellitus 2011 , 1462-1551		7
55	Localization of the ezrin binding epitope for advanced glycation endproducts. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 1570-80	5.6	6

54	Amylin in the periphery. <i>Scientific World Journal, The</i> , 2003 , 3, 163-75	2.2	6
53	Diabetic renal microvascular disease: the role of hypertension and ACE inhibitors. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1992 , 19, 23-7	3	6
52	Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and Fibrosis. <i>Genes</i> , 2010 , 1, 335-48	4.2	5
51	Diabetic patients and kidney protection: an attainable target. <i>Journal of Hypertension</i> , 2008 , 26, S3-7	1.9	5
50	Localization of the ezrin binding epitope for glycated proteins. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1043, 617-24	6.5	5
49	Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1043, 750-8	6.5	5
48	Extracellular matrix, growth factors and their interactions in the pathogenesis of diabetic kidney disease. <i>Nephrology</i> , 1996 , 2, 291-303	2.2	5
47	Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1325-33	4	4
46	Renal amylin binding in normotensive and hypertensive rats: effects of angiotensin converting enzyme inhibition with perindopril. <i>Journal of Hypertension</i> , 1997 , 15, 1245-52	1.9	4
45	Blockade of the renin-angiotensin system: better late than never. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 1113-5	7.4	4
44	Interactions between growth factors in the kidney: implications for progressive renal injury. <i>Kidney International</i> , 2003 , 63, 1584-5	9.9	4
43	Effects of advanced glycation end products on ezrin-dependent functions in LLC-PK1 proximal tubule cells. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1043, 609-16	6.5	4
42	Experimental diabetic nephropathy: Is it relevant to the human disease. <i>Nephrology</i> , 2000 , 5, 177-185	2.2	4
41	Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition. <i>Journal of Diabetes and Its Complications</i> , 1995 , 9, 318-22	3.2	4
40	Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease.. <i>Clinical Science</i> , 2022 , 136, 167-180	6.5	4
39	Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. <i>Diabetology International</i> , 2014 , 5, 1-20	2.3	3
38	Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial. <i>Nature Reviews Nephrology</i> , 2014 , 10, 547-8	14.9	3
37	Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. <i>Drugs and Aging</i> , 1996 , 8, 38-46	4.7	3

36	Nuclear scanning in the diagnosis and localization of parathyroid adenomas. <i>Medical Journal of Australia</i> , 1986 , 144, 521-2, 524	4	3
35	Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4[From proximal tubules is dispensable for diabetic kidney disease development. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 988-997	4.3	3
34	High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 791476	5.7	3
33	Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease. <i>Frontiers in Physiology</i> , 2020 , 11, 518	4.6	2
32	DIRECT study: a commentary. <i>Diabetes and Vascular Disease Research</i> , 2010 , 7, 319-20	3.3	2
31	Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007 , 4, 85-92		2
30	Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. <i>Diabetes Care</i> , 2006 , 29, 747-8; author reply 748-9	14.6	2
29	DOES COMBINED BLOCKADE OF THE RAS AND AGE FORMATION CONFER SUPERIOR RETROPROTECTION IN A HYPERTENSIVE MODEL OF DIABETIC NEPHROPATHY?. <i>Nephrology</i> , 2002 , 7, A68-A68	2.2	2
28	Turning up the heat: heat shock proteins, hypertension and cardiovascular risk. <i>Journal of Hypertension</i> , 2002 , 20, 1713-4	1.9	2
27	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria 1994 , 341-351		2
26	Antihypertensive Treatment in NIDDM, With Special Reference to Abnormal Albuminuria 1998 , 419-434		2
25	Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial. <i>Cmaj</i> , 2013 , 185, 1023-4	3.5	1
24	Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?. <i>Nature Reviews Endocrinology</i> , 2009 , 5, 138-9	15.2	1
23	Myocardial infarction increases ACE2 expression in rat and humans: reply. <i>European Heart Journal</i> , 2005 , 26, 1142-1143	9.5	1
22	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria 2000 , 441-459		1
21	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria 1996 , 385-396		1
20	The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes635-656		1
19	Pathogenesis of Macrovascular Complications in Diabetes 2016 , 599-628		1

18	Core Patient-Reported Outcomes (PROs) and PRO Measures (PROMs) for Polypharmacy Medicines Reviews: A Sequential Mixed-Methods Study. <i>Patient Preference and Adherence</i> , 2019 , 13, 2071-2087	2.4	1
17	Potential cardiorenal benefits of efglenatide in diabetes. <i>Nature Reviews Nephrology</i> , 2021 , 17, 708-709	4.9	1
16	Key profibrotic and pro-inflammatory pathways in the pathogenesis of diabetic kidney disease 2021 , 1, 15-26		1
15	Recent advances in the pharmacotherapeutic management of diabetic kidney disease.. <i>Expert Opinion on Pharmacotherapy</i> , 2022 , 23, 791-803	4	0
14	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. <i>Nephrology</i> , 2001 , 6, 290-297	2.2	
13	Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. <i>Medical Journal of Australia</i> , 2002 , 176, 296-297	4	
12	Internal medicine. <i>Medical Journal of Australia</i> , 2001 , 174, 9-11	4	
11	Vascular Endothelial Growth Factor as a Determinant of Diabetic Nephropathy 2006 , 187-199		
10	Advanced Glycation End-Products and Diabetic Renal Disease 2000 , 247-253		
9	THE IMPORTANCE OF BLOCKADE OF THE RENIN ANGIOTENSIN AND ENDOTHELIN SYSTEMS ON PROGRESSIVE RENAL INJURY IN SUBTOTALLY NEPHRECTOMISED RATS: USE OF COMBINATION REGIMENS. <i>Nephrology</i> , 2000 , 5, A109-A109	2.2	
8	LOSS OF CIRCADIAN RHYTHM OF BLOOD PRESSURE IN THE DIABETIC SHR COMPARED TO THE CONTROL SHR. <i>Nephrology</i> , 2000 , 5, A70-A70	2.2	
7	ACE and diabetes 2001 , 177-184		
6	Renal Microvascular Injury in Diabetes: RAGE and Redox Signaling. <i>Antioxidants and Redox Signaling</i> , 2006 , 061221112325002	8.4	
5	Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications 2007 , 219-228		
4	Microalbuminuria in diabetes. <i>Medical Journal of Australia</i> , 1994 , 161, 574-575	4	
3	Advanced Glycation End-Products and Diabetic Renal Disease 1998 , 257-262		
2	The Renin Angiotensin System 2011 , 323-335		
1	Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 2, 12-18	6.7	

